Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways Novartis is using this initiative to deepen its positioning as a “health equity partner” to government and community groups in Canada, with a fresher focus on women and gender‑diverse ...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
